Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opc-14117
- Development stage
- Phase 1
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
01
Overview
OPC-14117 is a small molecule drug developed as a lipophilic free radical scavenger and lipid peroxidation inhibitor. It was initially developed by Otsuka Pharmaceutical for neuroprotection in conditions such as cerebral ischemia and traumatic brain injury. The drug concentrates in the brain and has shown efficacy in reducing secondary cellular damage and cognitive dysfunction following cortical contusion in animal models. Its primary mechanism involves scavenging superoxide radicals to protect neuronal tissue from oxidative stress[3][8][5].
- Other names
- N-(7-Hydroxy-2,2,4,6-trimethylindan-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide7-Hydroxy-1-[2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamido]-2,2,4,6-tetramethylindan
Beyond the preview
Go deeper on opc-14117.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opc-14117.